PASW has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PASW has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ping An Biomedical Co Ltd PASW
Ping An Biomedical Co PASW +0.07% 17 Days Sales Outstanding is 266.15 as of Sep. 2025, which is 48% above its 10-year median of 179.77. GuruFocus rates PASW with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,036 Manufacturing - Apparel & Accessories companies, Ping An Biomedical Co ranks worse than 97.01% on this metric.
Ping An Biomedical Co's average Accounts Receivable for the six months ended in Sep. 2025 was $3.26 Mil. Ping An Biomedical Co's Revenue for the six months ended in Sep. 2025 was $2.23 Mil. Hence, Ping An Biomedical Co's Days Sales Outstanding for the six months ended in Sep. 2025 was 266.15.
The historical rank and industry rank for Ping An Biomedical Co's Days Sales Outstanding or its related term are showing as below:
During the past 5 years, Ping An Biomedical Co's highest Days Sales Outstanding was 313.35. The lowest was 175.71. And the median was 179.77.
Ping An Biomedical Co's Days Sales Outstanding increased from Sep. 2024 (215.68) to Sep. 2025 (266.15).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Ping An Biomedical Co (NAS:PASW) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
The historical data trend for Ping An Biomedical Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Ping An Biomedical Co Annual Data | |||||||||||
| Trend | Sep21 | Sep22 | Sep23 | Sep24 | Sep25 | ||||||
| Days Sales Outstanding | 179.77 | 175.71 | 235.09 | 179.33 | 308.05 | ||||||
| Ping An Biomedical Co Semi-Annual Data | |||||||||
| Sep21 | Mar22 | Sep22 | Mar23 | Sep23 | Mar24 | Sep24 | Mar25 | Sep25 | |
| Days Sales Outstanding | Get a 7-Day Free Trial |
|
151.83 | 211.75 | 215.68 | 357.53 | 266.15 | ||
For the Textile Manufacturing subindustry, Ping An Biomedical Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Ping An Biomedical Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ping An Biomedical Co's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Ping An Biomedical Co's Days Sales Outstanding for the fiscal year that ended in Sep. 2025 is calculated as
| Days Sales Outstanding (A: Sep. 2025 ) | |||||||||
| = | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
| = | ( (Accounts Receivable (A: Sep. 2024 ) | + | Accounts Receivable (A: Sep. 2025 )) | / | count ) | / | Revenue (A: Sep. 2025 ) | * | Days in Period |
| = | ( (5.715 | + | 2.377) | / | 2 ) | / | 4.794 | * | 365 |
| = | 4.046 | / | 4.794 | * | 365 | ||||
| = | 308.05 |
Ping An Biomedical Co's Days Sales Outstanding for the quarter that ended in Sep. 2025 is calculated as:
| Days Sales Outstanding (Q: Sep. 2025 ) | |||||||||
| = | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
| = | ( (Accounts Receivable (A: Mar. 2025 ) | + | Accounts Receivable (A: Sep. 2025 )) | / | count ) | / | Revenue (A: Sep. 2025 ) | * | Days in Period |
| = | ( (4.139 | + | 2.377) | / | 2 ) | / | 2.234 | * | 365 / 2 |
| = | 3.258 | / | 2.234 | * | 365 / 2 | ||||
| = | 266.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.